CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in CNS Pharmaceuticals, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +1 vs. Q1 2021
- Shares held
- 1.35M
- +72.8K (+5.7%) vs. Q1 2021
- Total value
- $2.64M
- −$403.0K (−13.2%) vs. Q1 2021
- New holders
- 7
- 3 more added
- Sold out
- 6
- 2 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 599,309 | $1.18M | 0.00% | +458,818+326.6% | Added |
| Renaissance Technologies LLC | 432,109 | $847.0K | 0.00% | −290,651−40.2% | Reduced |
| Geode Capital Management, LLC | 100,196 | $196.0K | 0.00% | +39,412+64.8% | Added |
| BlackRock Inc. | 41,586 | $82.0K | 0.00% | +41,586 | New |
| Northern Trust Corp | 32,094 | $63.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 20,745 | $41.0K | 0.00% | −20,565−49.8% | Reduced |
| Commonwealth Equity Services, LLC | 20,000 | $39.0K | 0.00% | +20,000 | New |
| State Street Corp | 17,988 | $35.0K | 0.00% | +17,988 | New |
| Wells Fargo & Company | 13,850 | $27.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 12,500 | $25.0K | 0.00% | 00.0% | Unchanged |
| Alpha Cubed Investments, LLC | 11,000 | $22.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 11,061 | $22.0K | 0.01% | +11,061 | New |
| Integrated Advisors Network LLC | 10,700 | $21.0K | 0.00% | 00.0% | Unchanged |
| Cambridge Investment Research Advisors, Inc. | 10,250 | $20.0K | 0.00% | +10,250 | New |
| Advisor Group Holdings, Inc. | 5,000 | $10.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,676 | $9.00K | 0.00% | +3,316+243.8% | Added |
| Bank of America Corp | 2,000 | $4.00K | 0.00% | +2,000 | New |
| Capital Analysts, LLC | 1,000 | $2.00K | 0.00% | 00.0% | Unchanged |
| Sterling Financial Planning, Inc. | 600 | $1.00K | 0.00% | +600 | New |
| Gradient Investments LLC | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −92,404−100.0% | Sold out |
| Essex Investment Management Co LLC | 0 | $0 | 0.00% | −59,565−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −43,659−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −13,747−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −11,566−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |